Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation
NCT06957145 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2025-09-03
Summary
The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) compared to the same cell types in healthy controls. Additionally, the potential clinical correlation of VISTA expression in the follow-up of MS and CIS patients will be examined. By elucidating the role of VISTA in the pathophysiology of MS, this study will contribute to the literature by exploring its potential as a biomarker and its relevance in the development of novel therapeutic strategies.
Specifically, this study will compare VISTA protein secretion in MS patients at the time of their first attack with that of healthy controls. Furthermore, changes in VISTA protein secretion will be assessed in blood samples collected at 6- and 12-month follow-ups, and the correlations of these changes with clinical and laboratory findings will be investigated.
Finally, this study aims to determine whether CD4+ and CD8+ T cells, monocytes, and T regulatory (Treg) subgroups in the first attack blood samples of MS patients exhibit similar functional properties in terms of VISTA protein secretion as their counterparts in healthy controls. To achieve this, monocytes and T cell subtypes will be stimulated, and their pro- and anti-inflammatory cytokine responses will be analyzed.
Conditions
- Multiple Sclerosis, MS
Sponsors & Collaborators
-
Koç University
lead OTHER
Principal Investigators
-
Rabia G Gozubatik Celik, Assoc. Prof. · Koç University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-06-30
- Primary Completion
- 2026-01-30
- Completion
- 2026-12-30
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
NCT02587195 ·Status: COMPLETED ·Phase: PHASE3
-
Dubousset Functional Test: an Investigation of Its Validity and Reliability in Individuals with Multiple Sclerosis
NCT06849882 ·Status: RECRUITING
-
Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study
NCT03624296 ·Status: UNKNOWN ·Phase: NA
-
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
NCT01755871 ·Status: TERMINATED ·Phase: PHASE4
-
Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study
NCT03369106 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination
NCT07135752 ·Status: RECRUITING ·Phase: NA
-
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
NCT05277740 ·Status: RECRUITING
-
Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MS
NCT04874597 ·Status: ACTIVE_NOT_RECRUITING
-
Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells
NCT01587690 ·Status: COMPLETED
-
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
NCT01517282 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Investigation of Subclinical Markers of Multiple Sclerosis
NCT04604041 ·Status: RECRUITING
-
Development and Evaluation of the Self-management Module in Patients With Multiple Sclerosis
NCT05209113 ·Status: UNKNOWN ·Phase: NA
-
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
NCT05816122 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.
NCT05777902 ·Status: TERMINATED ·Phase: PHASE4
-
STAT4 in Multiple Sclerosis by PCR and Flow Cytometry
NCT03893344 ·Status: COMPLETED
-
Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome
NCT06455332 ·Status: RECRUITING ·Phase: NA
-
Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis
NCT06283524 ·Status: COMPLETED
-
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 ·Status: TERMINATED ·Phase: PHASE2
-
Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.
NCT03486665 ·Status: UNKNOWN
-
Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients
NCT02142764 ·Status: COMPLETED ·Phase: NA
-
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
NCT04857489 ·Status: UNKNOWN
-
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
NCT06865274 ·Status: RECRUITING ·Phase: NA
-
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years
NCT01084798 ·Status: COMPLETED